Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.50p +1.29% 39.125p 38.25p 40.00p 40.00p 40.00p 40.00p 112,669.00 16:35:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.1 -4.5 -4.4 - 47.65

Immupharma Share Discussion Threads

Showing 6926 to 6947 of 6950 messages
Chat Pages: 278  277  276  275  274  273  272  271  270  269  268  267  Older
DateSubjectAuthorDiscuss
10/12/2016
07:46
So will imm meet the full patient target by year end? Getting tight now.
divmad
08/12/2016
11:24
No worries. We are due an RNS of course - both notifying us of the new patent as well as the all important status of patient recruitment for the Phase III trial.
longshanks
08/12/2016
11:02
Sorry, let me put my specs back on. Misread the date. I'll delete the post. (Saw the turn up in share price and read the last RNS thinking it was today's. )
brucie5
08/12/2016
10:39
Today's RNS reads like very good news, though not about lupus. Would SK kindly care to explain its import to shareholders?
brucie5
06/12/2016
08:30
www.centerwatch.com/clinical-trials/listings/external-studydetails.aspx?StudyID=NCT02504645&City=Phoenix&Country=Mauritius Found a list of sites while searching not updated since 7 november but says 30 recruiting,
barriew
25/11/2016
10:37
Sylviane Muller recently presented at the Meeting of TRANSAUTOPHAGY in Warsaw. The link below is to the programme for the conference and the full abstract will be found under oral presentations (no. 9). The title of her presentation is " Lysosomal HSPA8, a key element in the mechanism of action of therapeutic P140 peptide/Lupuzor" and shows that the mechanism of action for Lupuzor has been further defined. Essentially, it appears that Lupuzor inhibits heat shock protein HSPA8 which is associated with a number of diseases as well as the aging process. The abstract details how HSPA8 plays an important role in chaperone-mediated autophagy (CMA) which is one of the 3 main types of autophagy and is associated with lupus. The final sentence from the abstract:- " All these targeted effects concur to downregulate the excessive CMA activity that occurs in lupus and to “reconfigure” the immune system in an otherwise deleterious autoimmune context" hxxp://cost-transautophagy.eu/wp-content/uploads/2016/11/1st_Joint_Meeting_Book_of_Abstracts.pdf
bermudashorts
24/11/2016
09:47
A binary gamble. BUT: I do like charts, do like the story here c/o SK and others; and since 2017 seems to be the Year of Make or Break, I have decided to re-enter with a small amount on the basis that in the absence of BAD NEWS this is likely to go up sharply as we approach results. In the not unlikely event that it doubles, I will then sell half. FWIW.
brucie5
24/11/2016
08:41
Cheers SK.
waterloo01
23/11/2016
21:23
Courtesy of fingers' excellent charting thread [Epic FXD]
sicilian_kan
23/11/2016
17:19
Read the Edison note they quote that Anifolumab from AstraZeneca as the most immediate competitor.Either they have not done there research or don't expect Lupuzor to succeed but very strange no mention,any thoughts.
best1467
23/11/2016
15:15
If/When Lupuzor gets through Phase III unscathed and to market she may well find herself awarded a special Qazwsxedc69 medal (for services to my bank account).
qazwsxedc69
23/11/2016
13:42
Congratulations to Immupharma co founder and Lupuzor inventor Prof. Sylviane Muller who has received yet another award for her work on Lupuzor. She has received the Leon Velluz Award from the French Académie des Sciences - one of the oldest scientific academies in the World. Below are some of the awards already received in recognition of her discovery of Lupuzor and work in the field of autophagy:- award of excellence from the Endocrine Society and Pfizer the Apollo-B award from Roche CNRS Silver Medal CNRS Gold Medal Chevalier de l’Ordre de la Légion d’Honneur (2010).
bermudashorts
22/11/2016
11:08
In principle it shouldn't make any difference, but it is a key milestone and marks not only a 1st for IMM (hitting a deadline), but means the results are likely to be on-time, rather than delayed through slow recruitment and importantly means no (to date) adverse events. The next big reporting event would be the results, and I doubt we will be trading anywhere near this price as we get closer to those (even though we won't know if they are positive or not until they report) All IMO Edit: If we had outlicensed getting to full recruitment would be a milestone trigger.
waterloo01
22/11/2016
11:03
Not doubting you Waterloo, just a lack of knowledge on my part - does timely full recruitment typically have a specific positive impact on share price? I don't necessarily see why it should? Thanks.
qazwsxedc69
22/11/2016
09:42
Looking for a re rating here if they manage to get full recruitment complete by year end. Could/should see it touch the highs in the 70's/80's IMO
waterloo01
20/11/2016
10:23
Thanks for clarification on the target price although for those of us who have been here a while I don't think it changes our view on the prospects. I did top up again but that's about my limit now, definitely top heavy IMM but I can't see the same potential value anywhere else. I have my relatively safe investments and this as my risky punt.
pdt
19/11/2016
10:19
SK - thanks for the response (1503).
colsmith
18/11/2016
09:57
SK, Well certainly Vadim Alexandre didn't correct the interviewer when he was asked about the 137 target so both perhaps at fault. Having said that, it's the first time I've seen Vadim Alexandre interviewed and thought he was very impressive. A pleasant contrast perhaps to Dr. Mike Mitchell's (Panumure) rather quiet and low key approach.
bermudashorts
18/11/2016
09:12
Interviewee I think, but yes. See also: hTTps://www.thecerbatgem.com/2016/11/14/immupharma-plc-imm-earns-buy-rating-from-northland-securities-2.html
sicilian_kan
18/11/2016
09:09
Northland have not cut their price target, see: hTTp://www.nandp.co.uk/sharedealing/company/?companyCode=IMM Target price remains 171p.
sicilian_kan
18/11/2016
09:08
PDT, I can confirm that Northland's target price hasn't been cut and remains unchanged at 171p - the interviewer made a mistake!!
bermudashorts
17/11/2016
11:16
Looks like Northland have cut the Buy target from 171p to 137p. Bit academic really. Perhaps 171p was a bit embarrassing since it has stuck around 40p for a number of months. I wonder if any UK sites will be opened, I half expect an announcement in mid-December to say recruitment has been completed without any further locations being announced.
pdt
Chat Pages: 278  277  276  275  274  273  272  271  270  269  268  267  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20161211 10:03:17